Overview

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2029-11-20
Target enrollment:
Participant gender:
Summary
A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.
Phase:
PHASE2
Details
Lead Sponsor:
Henan Cancer Hospital
Treatments:
ARX788